Proliferin-related protein overexpression in SGC‑7901 gastric cancer cells inhibits in vitro cell growth and tumorigenesis in nude mice

He,Miao; Wang,Limin; Pu,Jun; Yang,Qiaozhen; Li,Gang; Hao,Jie

doi:10.3892/or.2013.2402

Proliferin-related protein overexpression in SGC‑7901 gastric cancer cells inhibits in vitro cell growth and tumorigenesis in nude mice

Authors:
- Miao He
- Limin Wang
- Jun Pu
- Qiaozhen Yang
- Gang Li
- Jie Hao
View Affiliations

Affiliations: Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, P.R. China, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: April 12, 2013 https://doi.org/10.3892/or.2013.2402
Pages: 2243-2248

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As reported in the literature, the worldwide 5-year overall survival rate for patients with gastric cancer receiving surgical treatment in the progressive stage is less than 25%. Therefore, there is an urgent need for the development of novel therapeutic strategies. Our preliminary studies demonstrated that proliferin-related protein (PRP) inhibits the proliferation of TM3 Leydig testicular cells. To evaluate whether PRP has antitumor effects in vitro and in vivo, we stably expressed PRP in SGC-7901 gastric carcinoma cells. PRP inhibited the proliferation and cell cycle progression of SCG-7901 cells, as determined by cell growth and cell cycle assays. Transwell experiments demonstrated that PRP inhibited the cell migration and invasion of SCG-7901 cells. Western blotting demonstrated that PRP-overexpressing cells had upregulated matrix metalloproteinase 9 (MMP-9) and downregulated tissue inhibitor of metalloproteinases-1 (TIMP-1). In a xenograft tumor formation assay using nude mice, tumors formed by PRP-overexpressing cells had significantly lower weights than those formed by control cells, and the tumor inhibitory rate reached 71.9%. We demonstrated for the first time that PRP inhibits gastric carcinoma cell proliferation, motility, and tumorigenicity in vivo, suggesting that PRP may become an important target for the development of gastric cancer gene therapy.

View Figures

View References

1	Foukakis T, Lundell L, Gubanski M and Lind PA: Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol. 46:277–285. 2007. View Article : Google Scholar
2	Robins D: Gene Therapy Protocols. Humana Press Inc; New Jersey: pp. 102–105. 1997
3	Meza-Junco J, Au HJ and Sawyer MB: Critical appraisal of trastuzumab in treatment of advanced stomach cancer. Cancer Manag Res. 3:57–64. 2011. View Article : Google Scholar : PubMed/NCBI
4	Bramhall SR, Hallissey MT, Whiting J, et al: Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 86:1864–1870. 2002. View Article : Google Scholar : PubMed/NCBI
5	McNamara MJ and Adelstein DJ: Current developments in the management of locally advanced esophageal cancer. Curr Oncol Rep. 14:342–349. 2012. View Article : Google Scholar : PubMed/NCBI
6	De Vita F, Giuliani F, Silvestris N, et al: Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets. 16(Suppl 2): S29–S34. 2012.PubMed/NCBI
7	Bachelot A and Binart N: Reproductive role of prolactin. Reproduction. 133:361–369. 2007. View Article : Google Scholar
8	Soares MJ, Konno T and Alam SM: The prolactin family: effectors of pregnancy-dependent adaptations. Trends Endocrinol Metab. 18:114–121. 2007. View Article : Google Scholar : PubMed/NCBI
9	Ben-Jonathan N, LaPensee CR and LaPensee EW: What can we learn from rodents about prolactin in humans? Endocr Rev. 29:1–41. 2008. View Article : Google Scholar : PubMed/NCBI
10	Haig D: Placental growth hormone-related proteins and prolactin-related proteins. Placenta. 29(Suppl A): S36–S41. 2008. View Article : Google Scholar : PubMed/NCBI
11	Linzer DI and Nathans D: A new member of the prolactin-growth hormone gene family expressed in mouse placenta. EMBO J. 4:1419–1423. 1985.PubMed/NCBI
12	Jackson D, Volpert OV, Bouck N and Linzer DI: Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science. 266:1581–1584. 1994. View Article : Google Scholar : PubMed/NCBI
13	Colosi P, Swiergiel JJ, Wilder EL, Oviedo A and Linzer DI: Characterization of proliferin-related protein. Mol Endocrinol. 2:579–586. 1988. View Article : Google Scholar : PubMed/NCBI
14	Toft DJ and Linzer DI: Identification of three prolactin-related hormones as markers of invasive trophoblasts in the rat. Biol Reprod. 63:519–525. 2000. View Article : Google Scholar : PubMed/NCBI
15	Lee SJ, Talamantes F, Wilder E, Linzer DI and Nathans D: Trophoblastic giant cells of the mouse placenta as the site of proliferin synthesis. Endocrinology. 122:1761–1768. 1988. View Article : Google Scholar : PubMed/NCBI
16	Zhao L, Hao J, Hu J, et al: Expression of proliferin-related protein in testis and the biological significance in testosterone production. Mol Cell Endocrinol. 343:25–31. 2011. View Article : Google Scholar : PubMed/NCBI
17	Bengtson NW and Linzer DI: Inhibition of tumor growth by the antiangiogenic placental hormone, proliferin-related protein. Mol Endocrinol. 14:1934–1943. 2000. View Article : Google Scholar : PubMed/NCBI
18	Schwartz GK and Shah MA: Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 23:9408–9421. 2005. View Article : Google Scholar : PubMed/NCBI
19	Dickson MA and Schwartz GK: Development of cell-cycle inhibitors for cancer therapy. Curr Oncol. 16:36–43. 2009.PubMed/NCBI
20	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
21	Klein T and Bischoff R: Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 41:271–290. 2011. View Article : Google Scholar : PubMed/NCBI
22	Cruz-Munoz W and Khokha R: The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci. 45:291–338. 2008. View Article : Google Scholar : PubMed/NCBI
23	Sier CF, Kubben FJ, Ganesh S, et al: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer. 74:413–417. 1996. View Article : Google Scholar : PubMed/NCBI
24	Bando E, Yonemura Y, Endou Y, et al: Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis. Oncol Rep. 5:1483–1488. 1998.PubMed/NCBI
25	Zhao F, Zhang Q, Kang C, et al: Suppression of matrix metalloproteinase-9 expression by RNA interference inhibits SGC7901 gastric adenocarcinoma cell growth and invasion in vitro and in vivo. Med Oncol. 27:774–784. 2010. View Article : Google Scholar : PubMed/NCBI